Impact of tamoxifen therapy on fertility in breast cancer survivors.
Impact of tamoxifen therapy on fertility in breast cancer survivors.
复制标题
DOI：
10.1016/j.fertnstert.2016.10.020
复制
发表时间：
2017-01
影响因子：
6.7
通讯作者：
Howards, Penelope P.
中科院分区：
文献类型：
--
作者：
Shandley, Lisa M.;Spencer, Jessica B.;Fothergill, Amy;Mertens, Ann C.;Manatunga, Amita;Paplomata, Elisavet;Howards, Penelope P.
确定他莫昔芬的使用是否与乳腺癌诊断后卵巢储备功能下降和生育可能性降低有关。进一步了解成人癌症、健康和生存 (FUCHSIA) 女性研究——基于人群的队列研究 不适用。 397 名年龄在 22 至 45 岁之间的女性乳腺癌幸存者，她们在 20 至 35 岁之间被诊断，且诊断后至少 2 年； 108 名幸存者也参加了诊所探访。无 癌症诊断后第一胎的时间、癌症后卵巢储备功能的临床测量（抗苗勒管激素 [AMH] 和窦卵泡计数 [AFC]） 与从未使用过他莫昔芬的女性相比，曾经使用过他莫昔芬的女性在乳腺癌诊断后生育孩子的可能性显着降低（风险比 [HR]=0.29，95% 置信区间 [CI]：0.16，0.54）。调整诊断年龄、烷化剂暴露和种族后，HR 为 0.25（95% CI：0.14，0.47）。然而，在调整潜在的混杂因素后，使用他莫昔芬的女性的 AMH 几何平均水平估计比从未服用过他莫昔芬的女性高 2.47 倍（95% CI：1.08，5.65）。当针对相同变量进行调整时，他莫昔芬组的 AFC 也高于非他莫昔芬使用者（风险比=1.21，95% CI：0.84，1.73）。与从未使用过他莫昔芬的幸存者相比，使用他莫昔芬的乳腺癌幸存者在癌症诊断后生育孩子的可能性较小。然而，与未使用他莫昔芬的人相比，使用他莫昔芬的人的卵巢储备功能并未下降。
To determine if tamoxifen use is associated with decreased ovarian reserve and decreased likelihood of having a child following breast cancer diagnosis. Furthering Understanding of Cancer, Health, and Survivorship in Adult (FUCHSIA) Women Study–a population-based cohort study Not applicable. Three hundred ninety-seven female breast cancer survivors aged 22–45 years who were diagnosed between ages 20–35 years and were at least 2 years post-diagnosis; 108 survivors also participated in a clinic visit. None Time to first child after cancer diagnosis, clinical measures of ovarian reserve (anti-Müllerian hormone [AMH] and antral follicle count [AFC]) after cancer Women who ever used tamoxifen were substantially less likely to have a child following breast cancer diagnosis (hazard ratio [HR]=0.29, 95% confidence interval [CI]: 0.16, 0.54) than women who had never used tamoxifen. After adjusting for age at diagnosis, exposure to an alkylating agent, and race, the HR was 0.25 (95% CI: 0.14, 0.47). However, after adjusting for potential confounders, women who had used tamoxifen had an estimated geometric mean AMH level 2.47 (95% CI: 1.08, 5.65) times higher than women who had never taken tamoxifen. AFC was also higher in the tamoxifen group compared to tamoxifen non-users when adjusted for the same variables (risk ratio=1.21, 95% CI: 0.84, 1.73). Breast cancer survivors who used tamoxifen were less likely to have a child following cancer diagnosis compared to survivors who never used tamoxifen. However, tamoxifen users did not have decreased ovarian reserve compared to tamoxifen non-users.
登录
查看更多内容
影响因子：
2.9
作者：
Quinn, Molly M.;Letourneau, Joseph M.;Rosen, Mitchell P.
通讯作者：
Rosen, Mitchell P.
影响因子：
168.9
作者：
Davies, Christina;Pan, Hongchao;Godwin, Jon;Gray, Richard;Arriagada, Rodrigo;Raina, Vinod;Abraham, Mirta;Medeiros Alencar, Victor Hugo;Badran, Atef;Bonfill, Xavier;Bradbury, Joan;Clarke, Michael;Collins, Rory;Davis, Susan R.;Delmestri, Antonella;Forbes, John F.;Haddad, Peiman;Hou, Ming-Feng;Inbar, Moshe;Khaled, Hussein;Kielanowska, Joanna;Kwan, Wing-Hong;Mathew, Beela S.;Mittra, Indraneel;Mueller, Bettina;Nicolucci, Antonio;Peralta, Octavio;Pernas, Fany;Petruzelka, Lubos;Pienkowski, Tadeusz;Radhika, Ramachandran;Rajan, Balakrishnan;Rubach, Maryna T.;Tort, Sera;Urrutia, Gerard;Valentini, Miriam;Wang, Yaochen;Peto, Richard
通讯作者：
Peto, Richard
DOI：
10.2147/dddt.s75266
发表时间：
2015
期刊：
Drug design, development and therapy
影响因子：
--
作者：
Pala Ş;Atilgan R;Ozkan ZS;Kavak SB;Ilhan N;Akpolat N;Sapmaz E
通讯作者：
Sapmaz E
影响因子：
168.9
作者：
Davies, C.;Godwin, J.;Gray, R.;Clarke, M.;Darby, S.;McGale, P.;Wang, Y. C.;Peto, R.;Pan, H. C.;Cutter, D.;Taylor, C.;Ingle, J.
通讯作者：
Ingle, J.
影响因子：
2.4
作者：
Metindir, J;Aslan, S;Bilir, G
通讯作者：
Bilir, G